Amprion � Protein Misfolding Cyclic Amplification (PMCA) Device

San Francisco-based Amprion, headed by CEO Russ Lebovitz, MD/PhD has developed a proprietary technology called Protein Misfolding Cyclic Amplification (PMCA), using CSF and plasma alpha-Synuclein (αS) to aid in the diagnosis of Parkinson’s disease. Their device has received a Breakthrough Device designation from U.S. FDA.

On Oct. 6th, 2021 Amprion has announced the commercial rollout of its innovative SYNTap Biomarker Test, a first-in-class laboratory-developed test (LDT) for accurate and reliable detection of α-synuclein aggregates, a hallmark in various brain diseases. The SYNTap Test aids in diagnosing synucleinopathies such as Parkinson’s, Lewy Body Dementia, and Multiple System Atrophy (MSA).

In addition, the novel test helps distinguish underlying synucleinopathies in other neurodegenerative conditions, such as Alzheimer’s. The SYNTap Test identifies prion-like α-synuclein aggregates using a few drops of CSF (about one hundred microliters), confirming the presence of progressive brain disease. Test results are intended to accompany other clinical and diagnostic findings for patient case management.